Most patients with advanced cancer eventually acquire resistance to targeted therapies, spurring extensive efforts to identify molecular events mediating therapy resistance. Many of these events involve synthetic rescue (SR) interactions, where the reduction in cancer cell viability caused by targeted gene inactivation is rescued by an adaptive alteration of another gene (the rescuer). Here we perform a genome-wide prediction of SR rescuer genes by analyzing tumor transcriptomics and survival data of 10,000 TCGA cancer patients.
INTRODUCTION
Despite major advances in cancer therapies, many patients eventually succumb to emerging resistance. Recent experimental and clinical studies have successfully characterized tumorspecific molecular signatures of resistance to targeted therapies through DNA and RNA sequencing(1-8). However, these studies require the arduous collection and molecular profiling of paired pre-and post-treatment tumor biopsies (9) and cannot be conducted for drugs at early stages of their development. Thus, the development of a computational approach that can expedite the identification of resistance determinants from existing large-scale cancer cohorts is warranted.
We set out to predict synthetic rescue (SR) interactions (1- 3, 10, 11) , which are a generalization of suppressor interactions (12) . Suppressor interactions, recently identified in yeast genome-wide (11) , denote a functional interaction where following the inactivation of specific genes cells suppress additional genes to escape from harmful alterations (13) (14) (15) . Their generalization, SR interactions, denotes a functional interaction where a fitness reducing alteration due to inactivation of one gene (termed the vulnerable gene) is compensated by altered activity (down-regulation or up-regulation) of another, rescuer gene (9, (16) (17) (18) (Figure 1a ). As rescue events are required to compensate for fitness reducing alterations occurring during the natural evolution of cancer (19) , one may expect to detect the SR interactions forged in evolving tumors, even untreated ones (20) (21) (22) . When a vulnerable gene is targeted by an anti-cancer drug (23) , such SR interactions may manifest by changes in the activity of its interacting rescuer gene(s), thus mediating drug resistance. Both primary and adaptive resistance could be mediated by SR mechanisms.
RESULTS
We and others have recently developed computational approaches to identify synthetic lethal (SL) interactions (24) (25) (26) (27) (28) (29) (30) , a widely studied class of genetic interactions. While SL interactions pinpoint molecular vulnerabilities in tumors that can be exploited to target them (31, 32) , SR interactions can rescue the cells from such vulnerabilities by actively modifying the interacting rescuers, leading to therapy resistance. As drugs mainly inhibit target genes, we focus herewith on two types of SR interactions (Figure 1a) ; (1) DU-SR interactions, where the Downregulation of a vulnerable gene is rescued by the Upregulation of a rescuer gene (2) (3) (4) (33) (34) (35) (36) ; and (2) DD-SR (suppressor) interactions, where the Downregulation of a vulnerable gene is rescued by the Downregulation of a rescuer gene (10, 11, 19, 37, 38) .
The INCISOR Pipeline and the resulting Cancer SR networks
To predict SR interactions, we developed a new data mining approach, termed (1) In vitro essentiality screens: This step mines in vitro genome-wide shRNA (39) (40) (41) (42) and drug response screens (43, 44) composed of 2.3 million measurements in 720 cancer cell lines.
Adopting a recent approach (29) , INCISOR systematically searches for candidate SR pairs. In cell lines with a given gene knockdown, it searches the cell-line's transcriptome for genes whose up-regulation is associated with increased cell growth. We term the first gene a vulnerable (V) gene and the second a candidate (DU) rescuer (R) gene.
(2) Molecular survival of the fittest (SoF): By analyzing TCGA gene expression and somatic copy number alterations (SCNA) of 8,749 patients across 28 cancer types, INCISOR selects candidate SR pairs from step 1 that are observed in their rescued state (gene R is specifically upregulated when gene V is inactive) significantly more than expected. This enrichment testifies to positive selection of samples in the rescued state, a key property of SR interactions.
(3) Patient survival screening: This step further selects those candidate SRs whose rescued state in TCGA tumor samples exhibits worse patient's survival, as the reduced survival can serve as an indicator of increased tumor fitness. INCISOR uses a stratified Cox proportional hazard model to establish this relation while controlling for confounding factors including cancer type, sex, age, genomic instability, tumor purity (45) , and ethnicity.
(4) Phylogenetic screening: Because functionally interacting genes known to co-evolve (28) in a species, we select SR pairs composed of genes with high phylogenetic similarity. The top 5% of phylogenetically similar pairs among the ones passing the previous steps are chosen as the final set of putative SR pairs.
The resulting DU-SR network, which is composed of all the pairwise interactions that pass all four steps described above, is scale-free (Figure 1c , Table S2 ,3) and consists of 1259 genes and 1195 interactions (see Suppl. Information 2.1 for DD-SR; interactive networks available online, Methods; Table S4 ,5). Gene enrichment analysis revealed that the network nodes are enriched in cancer and resistance pathways (Suppl. Information 3.5-3.7). We also find that the activation of predicted rescuers increases with advanced cancer stages (Suppl. proportional to the number of interactions they have). The complete network is provided in Fig. S1f .
Benchmarking INCISOR against a collection of published DU-SR Interactions
We first benchmarked the DU-SR predictions via a comparison to genes whose overexpression rescues cancer cells, via a set of genes that were previously shown to mediate cancer drug resistance (2, 36, (46) (47) (48) (49) (50) (51) (52) (Table S9 
Experimental testing of predicted DD-SR interactions of mTOR in Head & Neck

Cancer cell lines
Our first experiment tested DD-SR interactions involving mTOR, a key growth regulating kinase in Head & Neck Cancer. To test the predicted rescue interactions involving mTOR, we knocked down (KD) 2200 genes in an experimental screen in a head and neck cancer cell line (HN12) and experimentally identified the (DD) rescue events occurring due to a subsequent mTOR inhibition by rapamycin treatment. 45 of these KDs, about 2.1%, were rescued by mTOR inhibition in the screen (Table S10, Methods). Independently, we applied INCISOR to identify genes that are predicted to be rescued by mTOR inhibition in a statistically significant manner (FDR = 0.05,).
INCISOR predicted 17 such DD rescuer genes (Methods), 11 of which indeed overlapped with the 45 interactions identified experimentally ( Fig. S5b ). This yields a precision level of ~65% and recall of ~25% (Figure 2a , false positive rate < 0.003), a 31-fold increase over the 2.1% precision expected by chance. The validated rescuers were enriched with transcription factors, FoxO signaling and stress response genes (Table S30 ). We further validated the predicted DD-SR interactions of mTOR via multiple published in vitro shRNA (39) (40) (41) (42) 
Experimental testing of predicted DU-SR rescuers via Drug Combinations and siRNA in Head & Neck cancer
In the second experimental validation, we tested the ability of predicted DU-SRs to guide new synergistic drug combinations, where the combination of drugs hits both a primary cancer drug target and its predicted DU rescuer (Methods). We tested seven such predicted combinational therapies across five different head and neck cancer cell lines. We find that 5 out of 7 combinations predicted are indeed synergistic (Figure 2b , Methods, Suppl. Information 4.7, Fig.   S6 ,7). One validated pair involves PI3KCA and mTOR, which are important genes in the PI3K/AKT/mTOR pathway. PIK3CA activates AKT by converting PIP2 to PIP3(55), promoting cell growth and survival. mTOR also promotes cell growth and can activate AKT independent of PIK3CA(56), thus might compensate for PIK3CA inhibition and explain their synergism.
In a third experiment, we conducted small-scale siRNA experiments to confirm that the synergism observed in above drug combinations is due to direct gene targeting and not due to offtarget effects of drugs. To confirm that enhanced sensitivity of the PI3KCA inhibitor, BYL719, is indeed due to mTOR inhibition we directly targeted mTOR by siRNA and showed BYL719 enhanced sensitivity in 4 of these cell lines (Suppl. 
Targeting predicted DU-SR rescuers of DNMT1 sensitizes resistant NSCLC celllines to DNTM1 inhibitor
In the final and fourth in vitro experiment, we tested if targeting predicted DU rescuers could sensitize therapy-resistant tumor cells. We picked DNMT1 to test this hypothesis as it is a major hub in the DU-SR network ( Figure 1c ) and a key oncogene in non-small cell lung cancers (NSCLC). We studied 18 NSCLC cell lines (Methods) that are insensitive to Decitabine (a DNTM1 inhibitor). In each of these cell lines, we pharmacologically inhibited the 13 top predicted DU rescuers of DNTM1. A BLISS(57-59) independence model was used to estimate synergism, and its significance was determined by comparing expected vs. observed drug response of drug combinations across all doses tested (Methods). Targeting the predicted rescuers synergistically sensitized these cell lines to Decitabine in 71% of the 234 (13 rescuers x 18 cell lines) conditions tested. In contrast, pharmacologically inhibition of two top predicted DD rescuers of DNMT1 showed the opposite, antagonistic effects, in 64% of the 36 conditions tested, with no synergistic effects, as expected (Figure 3a) . Both the observed synergistic and antagonistic effects across cell lines were significant compared to control drug tested (P < 2.2E-16). We further confirmed the ability of predicted SR interactions to predict resistant tumor sensitization in a large published patient-derived cell line collection (59) Finally, PAK1 may compensate for DNMT1 inhibition because it independently regulates cell adhesion and motility. These results testify that some rescue interactions may be explained by molecular interactions between genes proximally located on signaling pathways (17, 18) (Figure   3b ). However, many of the emerging rescue interactions are not, either due to our limited knowledge of signaling pathways or due to functional interactions that go beyond the scope of the signaling pathways. 
Rescuer and vulnerable genes share functional annotations
SR interactions predict drug response in patients
We next turned to evaluate the ability of INCISOR to predict the response of cancer patients to cancer drug treatments (65, 66) by analyzing the transcriptomics of their pre-treated samples. To this end, we applied INCISOR to identify the rescuers of (the targets of) 28 FDAapproved cancer drugs (for which treatment response data is available in the TCGA collection).
During the identification of SR interactions of targets of a given drug, we removed from TCGA patients who were administered with that drug, to remove any potential circularity (Methods, Fig.   S10e ). To predict the response of an individual patient's to a given drug, we defined the drugtumor SR-score as the number of upregulated rescuers of the drug's targets in that patient's tumor (Methods). We reasoned that a drug is expected to be less effective in tumors where many of its DU rescuers are upregulated. Using a Cox model to control for confounding variables (Methods), we find that the SR-scores predict the patients' survival after treatment in a statistically significant manner for 22 of the 28 drugs tested (Figure 4a shows the result for the 26 drugs tested with hazard ratios > 1, Methods). Evaluating the patients' response in terms of tumor size (based on the RECIST criteria), we find that the non-responders exhibit significantly higher drug-SR rescue scores than the responders for 14 out of 19 drugs for which tumor size information was available, as expected (Figure 4b, Methods ). An analysis of independent (non-TCGA) ovarian(67) and breast cancer datasets(68) further shows that SRs successfully predict both primary and acquired therapy resistance (Suppl. Information 5.2). In contrast, a randomly shuffled network (generated by randomly shuffling rescuer genes for each drug target, maintaining the original SR node degree) fails to predict patients' response to any of the drugs tested, both in the survival based and response based analyses. Drug-SLs inferred from DAISY(27) also showed no predictive signal here (log rank P=0.49). Obviously, INCISOR cannot predict response to drugs without known gene targets. 
Comparative evaluation of INCISOR's performance in predicting drug response vs. other recent large-scale genomic methods
We compared the performance of INCISOR with other extant methods for predicting cancer drug 
SR interactions determine efficacy of immune checkpoint blockades in patients
Finally, we hypothesized that SR-mediated transcriptomic changes mediate resistance to Immune checkpoint blockade (ICB) (20) . Accordingly, we turned to study the ability of INCISOR to predict SRs that can account for key transcriptomic changes occurring in patients' tumors following checkpoint immunotherapy and to study the match between the rescuers predicted and key resistance modulators identified in mouse studies. To predict the SR rescuers of the checkpoint genes, we removed in vitro essentiality screens (step 1) from the INCISOR pipeline as they are conducted in in vitro systems lacking an immune component (Methods). We find that the pretreatment expression levels of INCISOR predicted rescuers of PD1 successfully predict resistance to PD1-blockade in melanoma patients (Figure 6a Table S29 for pathways enrichment). Notably, we find that anti-CTLA4 blockade can be DU-rescued by a class of
which are known to interact with MHC1 and facilitate cell death (74) , putting forward the potential benefits of combinations targeting these genes. Analyzing samples of post-treatment combination therapy involving both anti-PD1 and anti-CTLA4 we find that many DU/DD rescuers respond as predicted but their individual response is evidently weaker (Figure 6d) .
Notably, the expression of some of the rescuers is altered in the predicted direction already in ontreatment tumor biopsies ( Fig. S10h,i ), suggesting that these alterations are selected for and thus functionally significant (this does not occur for randomly chosen genes that are not rescuers (P < 2.2E-16)). curves. Expression of the predicted rescuer genes of PD1 (CTLA4) was used to train an SVM supervised predictor of PD1 (CTLA4) blockade. For comparison, we also display the ROC curves of supervised predictors trained on the expression of all genes (shown as "All") and on the expression of genes selected randomly and controlled for the number of rescuers predicted (shown as "Random"). predictions are limited to targeted therapies. Finally, and importantly, we show that SR mediates both primary and adaptive resistance in patients: e.g., we show that the pre-treatment expression data of TCGA tumors is predictive of their response to drug treatments (primary resistance, Figure 4 ) and on the other hand, SRs can predict the post-treatment alterations following checkpoint inhibitors (adaptive resistance, Figure 6b-d) .
Like many genome-wide approaches, INCISOR has several limitations, including pitfalls arising from gene co-expression and from correlations in the copy number alterations of proximal genes, which may lead to the inference of false positive SRs. We have verified that the SR interactions are not biased towards genes lying on the same chromosome (Suppl. Information 2.3). We aimed to mitigate false positives in the design of INCISOR by selecting candidate SR pairs only when they are additionally supported by the shRNA and phylogenetic data that testify to causal rescue effects. Although INCISOR explains molecular mechanism of resistance to targeted therapies, it fails to capture resistance mechanism of untargeted therapies. Further, for many drugs, resistance can emerge via mechanisms independent of SRs, e.g., resistance due to alteration in drug efflux. Finally, as this is the first genome-wide study of cancer SR interactions, we focused on identifying SRs that are common across many cancer types. Future studies, however, will further identify cancer type-specific SR networks as more data accumulates.
Multiple rescuer genes could rescue and cause resistance to a given cancer drug. Three different strategies could be adapted to prioritize gene target amongst such multiple rescuers to maximize their clinical benefit: First, INCISOR quantifies that extent of the rescue based on its clinical significance observed in patients, which is determined specifically and may be different for each rescuer gene. This could be used for prioritization. Second, post-treatment transcriptomic data from a patient's tumor, if available, could be used to further narrow down rescuer alterations specific to that tumor. Finally, combining experimental testing in a patient's tumor material using organoids or PDXs with INCISOR predictions would be a powerful approach to systematically identify true clinically relevant rescuer among the multiple predicted SR rescuers.
This study has focused on the genome-wide prediction of SR interactions. Evidently, different signaling functional and physical interactions may be manifested in these rescue interactions (Figure 3b-e ). SRs are much less known and studied compared to another type of genetic interactions, known as synthetic lethal (SL) interactions. The difference between SL interactions and DD-SR interactions is obvious, by definition. Their difference from DU-SR interactions is more intricate: It manifests itself in cells where a given gene is in its wild-type state and its partner interacting gene is knocked down; if the two genes SL-interact there will be no reduction in cellular fitness in that case, but if they DU-SR interact, then the knockdown will reduce cellular fitness (as the rescuer is not up-regulated). Consequently, our results demonstrate that a given cancer drug may be effective in cells where its predicted rescuer is in its wild-type state but may become resistant as it is over-expressed. As expected we found no overlap between predicted DU-SR interactions and SL interactions, predicted by a similar data-mining approach (30) (Suppl. Information 2.2).
In summary, we present a novel approach to tackle resistance to targeted and immune cancer therapy by mining thousands of tumors available in TCGA to infer cancer-specific SR interactions. We conducted cell lines experiments demonstrating that targeting predicted DU-SRs could sensitize therapy-resistant tumor cells, identifying synergistic drug combinations. As SR interactions are derived directly from analyzing the patients' clinical samples, they are more likely to be clinically relevant(8) than findings based on cell-screens and mouse models. Our results lay a basis for the development of new combination therapies based on the molecular characteristics of an individual patient's tumor to proactively overcome resistance in a precision based manner.
METHODS
The INCISOR pipeline for identifying SR interactions
INCISOR identifies candidate SR interactions employing four independent statistical screens (Figure 1b) , each tailored to test a distinct property of SR pairs. We describe here the identification process for the DU-type SR interactions (Down-Up interactions, where the up-regulation of rescuer genes compensates for the down-regulation of a vulnerable gene (e.g., by an inhibitor compound, Fig. S1a ). Then we discuss how to modify DU-INCISOR to detect the other SR types (DD, UD, and UU). We identify pan-cancer SRs (that are common across many cancer types) analyzing gene expression, somatic copy number alteration (SCNA), and patient survival data of TCGA (75) from 8,749 patients in 28 different cancer types. INCISOR also integrates predictions from TCGA data with genome-wide shRNA (39, 40, 42) and drug response (43, 44) screens in around 720 cell lines composing in the total of 2.3 million shRNA measurements. The same approach can be used to identify cancer type specific SRs, in an analogous manner. INCISOR is composed of four sequential steps (an FDR threshold was set 0.05 for each step): for additional details).
Interactive SR networks
The four types of SR networks for pan-cancer were created using Cytoscape (84) and are accessible online in an interactive manner at http://www.umiacs.umd.edu/~vinash85/private/SR/ (with username: "sr" and password:
"sr123").
Genomic instability index
Genomic instability index measures the relative amplification or deletion of genes in a tumor based on the SCNA. Given Z be the absolute of log ratio of SCNA of gene i in a sample relative to normal control, GII of the sample is given as (85) where r d k represents the rank normalized value of the k th screen of INCISOR.
Mapping of drugs to their gene targets
The drugs were mapped to their targets based on the mapping reported in CCLE, CTRP, and DrugBank (43, 86, 87) with exception of target genes whose mechanism of action is explicitly denoted as an agonist in DrugBank.
Effect size via Cohen's d
Throughout the manuscript, whenever applicable, to quantify a difference between two groups, we use an effect-size measure called cohen's d (88) . It is defined as the difference of means divided by pooled standard deviation. Given > and D as standard deviations of two groups and > and D are a number of samples in each group, the pooled standard deviation is defined as:
(4)
Pathway enrichment
GO, and KEGG enrichment analyses were conducted using R-packages clusterprofiler
and GOFunction using default settings.
Precision and Recall
Using standard definitions, we define INCISOR's precision as the fraction of true SR interaction among the predicted SR interaction by INCISOR. The INCISOR's recall is defined as the fraction of true SR interactions that are retrieved by INCISOR among all true SR interactions.
Benchmarking DU-SR networks using literature compiled SR interactions
The seven datasets of the published SR interactions were compiled using extensive literature survey of large clinical and experimental studies (Datasets, dataset pairs, and associated publications are listed in Table S9 ). Each dataset consists of a drug and experientially and/or clinically validated genes whose over-expression cause resistance to the drug treatment in patient samples/cell lines. In each study, the pairings between the drug targets (vulnerable genes) and the corresponding resistance-causing genes (rescuer genes) form the positive set; and the pairings between the targets and all other genes tested, which do not exhibit resistance, forms the negative set. Using the INCISOR interaction-score of individual SR-pairs as the prediction for the strength of SR interaction, we performed standard ROC and precision-recall analysis (Suppl.
Information 4.1).
Constructing the drug DU-SR network
To remove any potential circularity in drug response prediction, for each drug analyzed, we excluded from TCGA dataset the samples of the patients who were treated with that drug. Next, we applied INCISOR to the remaining TCGA samples to identify rescuers of the targets of the drug. The resultant drug-DU-SR network applied for 28 targeted drugs constitutes 182 rescuer genes of 24 drug targets (Suppl. Information 5.1).
Predicting pan-cancer drug response in patients
Prediction of drug response using patient survival: Using the drug-DU-SR network, we analyzed 4,328 TCGA samples, which is the collection of samples of patients who were treated with the drugs that were administered to at least 30 patients in TCGA. We predicted that patient tumors would be resistant to drug treatment if multiple DU rescuer genes of the drug targets are upregulated in their tumor. Therefore, the number of rescuer gene over-expressed will be predictive of patients' drug response. Accordingly, for a drug tested D and each patient administering D, we estimate the fraction (C ) of DU rescuer genes upregulated of its drug targets (deduced from their gene expression and SCNA values in the pre-treatment tumor sample) in the patient sample. To predict the response of TCGA patients treated, we evaluated the association of C with the patients' survival using stratified Cox model, which also controls for confounding factors(cancer-type, age, sex, and race) as follows: h 3 t, patient~h ;3 t, patient exp β > C + β D age + β F GII ,
Where h 3 , h ;3 , βs age, and GII are defined as in the equation (1). Co-variates C, age, and GII are quantiles normalized to N(0,1). The significance of β > , which is the coefficient of C, is determined by comparing the likelihood of the model with the NULL Cox model, which is similar to (3) but without the covariates C, followed by likelihood ratio and Wald's tests (77, 78) . As evident, SRs can be successfully used to predict drug response in an unsupervised manner (which is hence less prone to over-fitting).
Prediction of patient drug response based on post-treatment patient tumor size:
We To predict the response of a drug in a supervised manner, we first identified responders and non-responders in TCGA dataset. Given the CFE occurrence matrix as features described above, we built a random forest based supervised predictor that discriminates responders from non-responders. The random forest was preferred over SVM because its performance was superior as compared to SVM for this prediction task.
Twofold cross-validation was used to estimate AUC. 
Experimental testing of INCISOR-predicted SR interactions involving mTOR
We used Rapamycin because it is a highly specific mTOR inhibitor and hence enables targeting of a predicted rescuer gene by a highly specific drug, combined with the ability to knock down predicted vulnerable genes in a clinically-relevant lab setting.
Rapamycin is known to specifically targets mTOR in its complex 1 (89) . Its selectivity stems from the need to act on a protein FKBP12, which binds to the FKBP12-binding region (FRB) in mTOR (90) . This was confirmed in our earlier work (91) (particularly in the HN12 cell line, which we used in our experiment) by expressing an FRB mutant mTOR that cannot bind to the rapamycin-FKBP12 complex, which rescued these cells from the anti-tumor effect of Rapamycin in vitro and in vivo. This retro-inhibition approach further supported the specificity of rapamycin for mTOR, in a biologically relevant context. And therefore we choose HN12 to conduct this experiment. Information 4.6). We performed the shRNA knockout and mTOR inhibition in the following steps. 2214 gene kinases (Table S10) Significant experimental (DD) rescue event was determined by using Mageck (92) , where read counts from pooled shRNA were the first median normalized for both rapamycin treated samples (3 replicates) and controls (3 replicates). The difference of read counts in rapamycin-treated samples and controls was then modeled as a negative binomial model and was used to test if the difference is significant for each gene tested in pooled shRNA (92) .
Next, we applied INCISOR to TCGA to specifically predict DD-SR interactions between 2214 genes tested and mTOR as DD rescuer. Each gene pairing (between 2214 genes and mTOR) were quantified using INCISOR interaction-score. The score was used to estimate precision and recall.
To quantify the lethality of vulnerable knockdown in the experiment, we performed a one-sided Wilcoxon rank-sum test between initial normalized count with in vivo normalized count for in vivo lethality (and with the untreated normalized count for in vitro lethality). To compare rescue effect of Rapamycin treatment between shRNA knockdown of mTOR's vulnerable gene partner and control gene knockdown, we performed a one-sided Wilcoxon rank-sum test between Rapamycin effects of mTOR partner vulnerable genes and control genes. growth rate X = normalized count(X) initial normalized count(X) Effect of Rapamycin treatment on cell growth on knockdown of gene X was calculated as:
rapamycin effect(X) = treated growth rate(X) mean untreated growth rate(X)
Experimental Testing of SR-predicted Synergistic Drug Combinations in head and neck cancer cell lines
Seven drug combinations tested in this experiment were chosen as follows. Among the important cancer genes captured by DU-SR network, we focused on testing SR interactions between 5 important HNSC oncogenes (mTOR, PIK3CA, KIT, AKT, and PTK2). INCISOR predicted 5 SR-DU interaction between these oncogenes. Two different inhibitors (Rapamycin and ink128) were included for mTOR, and one inhibitor each for PIK3CA, KIT/SRC, AKT and PTK2 were included in the experiment. This resulted seven combinations tested (Figure 2b) .
Rapamycin was purchased from LC Laboratories (Woburn, MA). Dasatinib, Erlotinib, BYL719, INK128 were purchased from Selleckchem (Houston, TX).Vita-Blue Cell Viability Reagent was purchased from Bio-tools (Jupiter, FL). CAL33, HN12, Detroit 562 and SCC47 cell lines were cultured in 96-well-plate, then treated with drugs for 48 hours (Raw Data in Table S11-17). Assays were performed according to the manufacturer's instructions. Combination index for quantitation of drug synergy was analyzed by CompuSyn software (93, 94) . CI values represent synergism (CI<1), additivity (CI=1), and antagonism (CI>1), respectively (Suppl. Information 4.7).
Experimental Testing of SR-predicted rescuers via siRNA
siRNAs for non-targeting control and PIK3CA were purchased from GE Healthcare (two ON-TARGETplus PIK3CA siRNAs 5'-GCGAAAUUCUCACACUAUU, and 5'-GACCCUAGCCUUAGAUAAA, Lafayette, CO). siRNAs for mTOR were purchased from Sigma (two MISSION® siRNA human mTOR SASI_Hs02_00338641 and SASI_Hs01_00203144). Cells were cultured in 96-well-plate, transfected with lipofectamin RNAiMAX reagent (Life Technologies, Carlsbad, CA) for 24 hours, then cells were treated with drugs for another 48 hours (Raw Data in Table S18, 19) . Viability assays were completed as previous described (Suppl . Information 4.7) .
To test whether the KD of INCISOR-predicted rescuers acts as sensitizers, we checked the sensitivity of cells to the primary drug increases upon the KD of the rescuer. The efficacy of the rescuer KD to sensitizes cancer cells to a primary drug was estimated as the percentage increase in the sensitivity to the drug following the rescuer KD relative to the sensitivity of the primary drug alone without rescuer KD. Specifically, we used a targeted siRNA to knockdown the specific rescuer gene, while an untargeted non-specific siRNA was used as a control. Cell counts were measured for the untargeted/targeted siRNA post primary drug treatments. The normalized-response of (targeted/untargeted) siRNA-treated-cells to drug treatment was quantified as a change in cell counts relative to the cell counts following the respective siRNA inhibition alone. Next, using this normalized-response, DRC was estimated for both targeted and untargeted siRNA using DRC R-package. Percentage increase in sensitivity of the primary therapy (Y-axis, Fig.   S8i ) due to the rescuer siRNA-KD was estimated as the percentage decrease in IC50 of the combination of primary drug treatment and siRNA inhibition relative to the primary therapy in untargeted siRNA combination. The significance of the increase in drug response was estimated using a standard ANOVA test.
Drug combination testing of SR interaction involving DNMT1
Drug combination Screen
Drug screening was performed using automated liquid handling in a 1536 well plate format (59) . The drug doses used were chosen based on previous single agent screening at the Center for Molecular Therapeutics of the Massachusetts General Hospital Center for Cancer Research (Table S24 ).
The screen of two drug A and B was performed in a 1x5 format with one dose of drug A combined to 5 doses of drug B and compared to the effects of the five doses of drug B alone. The five doses of drug B followed a four-fold dilution series (Table S24, 25) .
Cells were seeded at densities optimized for proliferation based on the pre-screen experimental determination in 1536 well plate format. Cells were seeded, placed overnight at 37°C and drugs added the next day using a pin tool. After five days in drug cells were fixed permeabilized and nuclei stained in a single step by adding a PBS Triton X100 / Formaldehyde / Hoechst-33342 solution directly to the culture medium. Final concentrations: 0.05% Triton X-100 / 1% Formaldehyde / 1 ug/ml Hoechst-33342. Plates were covered and placed at 4°C until imaging.
Imaging was performed on an ImageXpress Micro XL (Molecular Devices) using a 4X objective. Cell nuclei enumeration was performed using the MetaXpress software, and count accuracy were routinely checked visually during acquisition. The screening was conducted in two replicate (two separate 1536 well plates, Table S25 ).
Calculation of drug combination synergy score
Due to a limited number of dose combination used in the experiments per each drug pair (1 concentration of Decitabine (five replicates) and five concentration of each rescuer inhibitor (2 replicates)), Fa-CI analysis is not feasible. The drug dose tested are provided in Table S24 .
We used Bliss independence model (57) (58) (59) to determine synergistic drug combination which is suitable per such experimental setting. More specifically, to determine Decitabine synergism with a rescuer inhibitor (R) tested in a cell line, we compared following two ratios of experimentally determined cell counts for each dose (C) of rescuer inhibitor (Table S25) : Table S26 ).
Analogously, R was considered to be significantly antagonistic with Decitabine, if Synergism R < 0.75 and p-value adjusted for multiple hypothesis corrections are less .05 (i.e., FDR < 0.05, Table S26 ).
Functional similarity of SR
Gene ontology similarity: Gene ontology semantic similarity(95) was used to quantify the similarity of GO terms between a gene pair. When multiple GO terms were associated with a gene, similarity between all combinations of rescuer GO terms, and vulnerable GO terms were calculated, and the maximum of these scores was taken as final similarity score (average of scores as final similarity gives similar result qualitatively). Distribution of GO similarity of DU-SR pairs was compared with two sets of controls: (a) shuffled network: interactions between rescuer and vulnerable genes of DU-SR network randomly shuffled, and (b) random network: gene pairs selected randomly from all protein-coding genes and controlled for similar degree distribution as the original DU-SR network. For each set of control, we determined the similarity measure in an analogous manner as described above for DU-SR network. Wilcoxon rank sum test was used to calculate the significance of GO similarity of DU-SR network relative to each control.
PPI distance: IGraph was used to estimate the distance between two genes in human protein-protein interactions (PPI) network compiled from (96, 97) . The PPI distance between gene pairs was compared with two controls the random network and shuffled network as described above.
STRING database distance: The STRING network version 10 was downloaded using Rpackage StringDB. STRING database is composed of gene pairs that are likely to share functional similarities. The functional similarity scores provided in the database were estimated using various sources including direct (physical) and indirect (functional) associations. The comparison control networks were made analogous manner as in case of GO similarity described above.
For DD-SR network GO similarity, PPI distance, and STRING database distance were estimated analogously (Suppl. Information 3.8).
PPI specific DU-SR interactions
To identify DU-SR interactions likely to be mediated by PPI interactions, we applied INCISOR on human PPI network compiled from (96, 97) . The details of the analysis and resultant network are provided in Suppl. Information 3.4. The enrichment of cancer driver genes in PPI-SR network was calculated using Fisher exact test.
Identification of DU and DD rescuers of immune checkpoints
To identify rescuers of immune checkpoints we removed filtering step 1 (in vitro essentiality screens) from INCISOR because the dataset used in step 1 were conducted in in vitro models that are deficient of the immune system. Next, we applied the INCISOR to the TCGA to identify the DU and DD rescuers of PD1/PDL1 and CTLA4 downregulation. We call an SR identified by INCISOR as clinically significant if the interaction shows association with survival either in pancancer or melanoma cohort in TCGA patient dataset.
Immunotherapy samples patient samples collection and processing
Patient samples
A cohort of patients with metastatic melanoma treated was enrolled in clinical trials 
